| Filed On | Filing |
|---|---|
| 07 Feb 2022 |
8-K/A: Financial Statements and Exhibits
On November 19, 2021, Pacira BioSciences, Inc. (“Pacira” or the “Company”) completed the acquisition (the “Acquisition”) of Flexion Therapeutics, Inc. (“Flexion”), pursuant to an Agreement and Plan of Merger, dated October 11, 2021, by a... |
| 06 Aug 2020 |
8-K/A: Results of Operations and Financial Condition
-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- |
| 25 Jun 2019 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying consolidated financial statements of MyoScience, Inc., and its subsidiaries (the Company), which comprise the consolidated balance sheets as of December 31, 2018 and 2017, and the related consolidated sta... |
| 07 Mar 2014 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On March 4, 2014, the Board of Directors (the “Board”) of Pacira Pharmaceuticals, Inc. (the “Company”) appointed Dr. Yvonne Greenstreet to serve as a Class III director. |
| 22 Jan 2014 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported, at the Company’s 2013 annual meeting of stockholders the option regarding the frequency (every year, every two years or every three years) of the advisory vote to approve the compensation of the Company’s named ex... |
Loading...